Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients


Cakirca M. , Karatoprak C. , Zorlu M. , Kiskac M. , Kanat M., CIKRIKCIOGLU M. A. , et al.

DRUG DESIGN DEVELOPMENT AND THERAPY, cilt.8, ss.239-243, 2014 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 8
  • Basım Tarihi: 2014
  • Doi Numarası: 10.2147/dddt.s52545
  • Dergi Adı: DRUG DESIGN DEVELOPMENT AND THERAPY
  • Sayfa Sayısı: ss.239-243

Özet

Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.